Document Detail


Aclarubicin in the treatment of multiple myeloma.
MedLine Citation:
PMID:  6384577     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fourteen patients with multiple myeloma received aclarubicin (ACR) intravenous drip infusion at a dose of 15-25 mg/m2/day for 7 days every 3 weeks. Nine of the patients achieved more than a 25% reduction in M-protein. In two of the nine the reduction was more than 50% and the duration of their responses was 2.0 and 2.8 months, respectively. In the nine cases of previous combination chemotherapy-resistant multiple myeloma, five showed more than a 25% reduction and one of them showed more than a 50% reduction in M-protein. One of the two patients with tumors achieved a marked regression of the tumor mass and two of the 14 patients showed marked improvement in subjective symptoms. Hematological toxicity, anorexia, nausea and vomiting occurred frequently. However, no cardiac toxicity obviously attributable to ACR was detected, and alopecia was generally mild. Thus, the above results indicate that ACR may be useful in combination chemotherapy for multiple myeloma because of its effectiveness and relatively low dose-limiting factors.
Authors:
T Sezaki; T Adachi; H Ishii; K Asano; I Takahashi; I Kimura
Related Documents :
20089967 - Stem cell transplantation in multiple myeloma: impact of response failure with thalidom...
20709667 - Improved survival for multiple myeloma in denmark based on autologous stem cell transpl...
466107 - Spinal-cord compression in myeloma.
11981007 - Effects of long-term intravenous ibandronate therapy on skeletal-related events, surviv...
23137997 - Assessment of a new scoring system for predicting non-sentinel node positivity in senti...
22904407 - Cb2-05: chemotherapy treatment patterns among advanced colon cancer patients.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Japanese journal of clinical oncology     Volume:  14     ISSN:  0368-2811     ISO Abbreviation:  Jpn. J. Clin. Oncol.     Publication Date:  1984 Sep 
Date Detail:
Created Date:  1984-11-02     Completed Date:  1984-11-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0313225     Medline TA:  Jpn J Clin Oncol     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  353-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aclarubicin
Adult
Aged
Antibiotics, Antineoplastic / therapeutic use*
Antineoplastic Agents / therapeutic use
Clinical Trials as Topic
Drug Resistance
Female
Humans
Immunoglobulins / analysis
Infusions, Parenteral
Male
Middle Aged
Multiple Myeloma / drug therapy*,  immunology,  pathology
Naphthacenes / administration & dosage,  therapeutic use
Neoplasm Staging
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Antineoplastic Agents; 0/Immunoglobulins; 0/Naphthacenes; 57576-44-0/Aclarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The value of ultrasonography in early detection of renal cell carcinoma.
Next Document:  Diagnosis of small carcinoma of the pancreas: importance of ultrasound scanning and endoscopic retro...